Molbio Diagnostics Ltd. IPO Review 2026: Listing Dates, Allotment, GMP & Overview
Molbio Diagnostics IPO is a Book Build Issue comprising a ₹200 crore fresh issue and an offer for sale of 91.66 lakh shares. The IPO opens on August 10, 2026 and closes on August 12, 2026. The price band is yet to be declared. Molbio Diagnostics develops molecular diagnostics solutions through its proprietary Truenat platform and is proposed to list on NSE and BSE on August 17, 2026.
Molbio Diagnostics IPO 2026
Molbio Diagnostics IPO is a Book Build Issue comprising a fresh issue of ₹200 crore and an offer for sale of 91.66 lakh shares. The IPO opens for subscription on August 10, 2026 and closes on August 12, 2026. The price band is yet to be declared. Molbio Diagnostics is a molecular diagnostics company known for its portable Truenat platform.
Molbio Diagnostics IPO Details
| IPO Open Date | August 10, 2026 |
| IPO Close Date | August 12, 2026 |
| Issue Size | Fresh Issue of ₹200 Crore + OFS |
| Price Band | To be declared |
| Lot Size | To be declared |
| Face Value | ₹1 per share |
| Issue Type | Bookbuilding IPO |
| Sale Type | Fresh Capital Cum OFS |
| Fresh Issue | ₹200 Crore |
| Offer for Sale | 91,66,000 Shares |
| Listing | NSE and BSE |
| Tentative Listing Date | August 17, 2026 |
| Lead Manager | Kotak Mahindra Capital Co. Ltd. |
| Registrar | KFin Technologies Ltd. |
Molbio Diagnostics IPO Timetable
| IPO Opens | August 10, 2026 |
| IPO Closes | August 12, 2026 |
| Allotment | August 13, 2026 |
| Refund | August 14, 2026 |
| Credit of Shares | August 14, 2026 |
| Listing | August 17, 2026 |
Refer to DRHP for detailed information.
About Molbio Diagnostics Ltd.
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care molecular diagnostics company engaged in the research, development, manufacturing and commercialisation of diagnostic solutions for infectious and non-communicable diseases.
The company has developed its proprietary Truenat platform, a portable and battery-operated PCR-based molecular diagnostics system designed for resource-limited settings. The platform is designed to provide molecular diagnostic results within an hour.
Molbio offers molecular testing solutions for more than 30 diseases through 43 diagnostic assays, covering areas including tuberculosis, COVID-19, HIV, Hepatitis B & C and HPV. The company also provides radiology, digital pathology and breast health screening solutions through subsidiaries and strategic collaborations.
Molbio operates six manufacturing facilities across India and serves customers in more than 90 countries, including government health programmes, diagnostic laboratories, hospitals and international healthcare organisations. As of March 31, 2026, the company employed 1,225 permanent employees.
Competitive Strengths
- Proprietary Truenat platform with WHO-endorsed TB molecular diagnostic technology.
- Strong research and development capabilities supported by a global patent portfolio.
- Scalable diagnostics business supported by recurring diagnostic test kit revenues.
- Global presence across more than 90 countries with government and institutional customers.
- Strategic acquisitions and collaborations supporting portfolio expansion.
- Experienced management team with expertise in molecular diagnostics and healthcare innovation.
IPO Allotment & Application Status
Registrar: Kfin Technologies Ltd.
- NSE Bid Status: https://www.nseindia.com/invest/check-trades-bids-verify-ipo-bids
- BSE Bid Status: https://www.bseindia.com/investors/appli_check.aspx
Empower your IPO investment journey — stay informed with accurate dates, price band and filings.
Track Live & Upcoming IPOs
Molbio Diagnostics IPO – Frequently Asked Questions
What are the Molbio Diagnostics IPO dates?
Molbio Diagnostics IPO opens on August 10, 2026 and closes on August 12, 2026.
What is the Molbio Diagnostics IPO price band?
The price band has not yet been declared.
What is the size of the Molbio Diagnostics IPO?
The IPO comprises a fresh issue of ₹200 crore and an offer for sale of 91.66 lakh shares. The final issue size will depend on the applicable offer price and other issue details.
Where will Molbio Diagnostics IPO be listed?
Molbio Diagnostics is proposed to be listed on the NSE and BSE, with August 17, 2026 as the tentative listing date.
What does Molbio Diagnostics do?
Molbio Diagnostics develops, manufactures and commercialises point-of-care molecular diagnostic solutions. Its proprietary Truenat platform is a portable PCR-based system designed for rapid molecular testing.
What is the Truenat platform?
Truenat is Molbio Diagnostics' portable, battery-operated PCR-based molecular diagnostics platform designed to enable molecular testing in resource-limited settings.
Investor Education Hub: Everything You Need to Know About IPOs
- How to Analyse an IPO Before Applying
- Step-by-Step Guide: IPO Process in India
- Understanding IPO Application & Allotment (UPI / ASBA & Eligibility)
- 8 Tips to Improve Your Chances of IPO Allotment
- Upcoming IPOs in India
- Investment Banking Services in India
Disclaimer: - Investments in IPOs are subject to market risks. Investors should read the Red Herring Prospectus carefully and consult their financial advisor before investing. https://www.mnclgroup.com/research-disclaimer
